EUVIMEDEUVIMED entdecken
Crossref

Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma

Miao Hao, Chen-Rui Liu, Meng Zhang, Xia-Qing Zhou, Zi-Cheng Jiang, Xiao-Hong Gao, Xin Zhang, Wen-Jun Wang, Yi-Kai Wang, Xiao-Li Jia, Ya-Ping Li, Shuang-Suo Dang

World Journal of Gastrointestinal Oncology · 15.11.2026 · 18 (11)

DOI: 10.4251/wjgo.123962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.11.2026. Verfasst von Miao Hao und 11 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The proportion of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is as high as 85.69% among HCC patients in China. Current anti-HBV drugs include nucleos(t)ide analogs (NAs) and interferon (IFN). AIM To compare the impact of NAs and IFN therapy on the occurrence of HCC in patients at high risk of HBV-related HCC. METHODS We enrolled 368 patients with high risk of HBV-related HCC, and 120 received subcutaneous injections of IFN, with or without NAs, constituting the IFN group. The remaining 248 patients were assigned to the NAs group, and received treatment with NAs alone. RESULTS For patients with a high risk of HBV-related HCC, after a 5-year treatment period, HCC incidence in the IFN group was 2.54%, while the NAs group showed a significantly higher incidence of 25.74% (P < 0.001). After propensity score matching, HCC incidence in the IFN and NAs groups was 2.94% and 22.0%, respectively (P < 0.001). CONCLUSION IFN-based therapy, compared with NAs, significantly reduced the risk of HCC in patients with high risk of HBV-related HCC.

Zitieren

APA

Hao, M., Liu, C., Zhang, M., Zhou, X., Jiang, Z., Gao, X., Zhang, X., Wang, W., Wang, Y., Jia, X., Li, Y., & Dang, S. (2026). Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 18(11). https://doi.org/10.4251/wjgo.123962

Vancouver

Hao M, Liu C, Zhang M, Zhou X, Jiang Z, Gao X, et al. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. 2026;18(11). doi:10.4251/wjgo.123962

BibTeX
@article{Hao2026,
  author = {Hao, Miao and Liu, Chen-Rui and Zhang, Meng and Zhou, Xia-Qing and Jiang, Zi-Cheng and Gao, Xiao-Hong and Zhang, Xin and Wang, Wen-Jun and Wang, Yi-Kai and Jia, Xiao-Li and Li, Ya-Ping and Dang, Shuang-Suo},
  title = {Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {11},
  doi = {10.4251/wjgo.123962}
}
Kostenlos starten →